Canadian and US Cannabis Edibles and Consumer Products Market Set to Explode to US$ 4.1 Billion by 2022
Canopy Growth CEO Bruce Linton: “…related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol, sleep aids, appetite aids, sports drinks, medicines and pet care.”
If you can read them, the signs are there.
The marijuana edibles industry, that part of the recreational marijuana that be ingested as a candy, a chocolate, a candy bar or in a mixed drink or a beer is going to be huge and may very well eclipse that old standby the smokeable flower or bud.
During the summer ResearchAndMarkets predicted that the global cannabis infused edible products market would grow at an expected CAGR of 25.01% from 2018 to 2022. The infused beverage market would include CBD based
recovery drinks and tonics as well as potent THC infused beers.
An October 11, press release announcing a new report, “The Tasty Future of Cannabis Edibles,” by BDS Analytics and Arcview Research predicted that by 2022 the edibles market would exceed US$4.1 billion, up from US$1.5 billion, for the Canadian and US market in 2018.
A June article in Forbes ran the headline “New Data Shows that Smoking Marijuana is a Dying Trend.” The data it references is the 2018 Deloitte report on the emerging Canadian marijuana market and the Forbes story says, A recent analysis from Deloitte shows that “smokable marijuana” in the northern nation will generate in upwards of $5 billion in 2019. But the edibles sector is predicted to hit somewhere between $12 and $22 billion by the time the market is in full swing.”
According to the BDS and Arcview report the THC infused candy and chocolate market segment took the lion’s share of the US market at 60%. The press release quotes Troy Dayton the CEO of ArcView Market Research: “Established big brand food and beverage companies are beginning to take notice of the cannabis edibles market and this is likely just the tip of the iceberg.”
If anyone doubts that edibles and beverages are the next big thing they should remember Constellation Brands $4 billion investment in Canopy Growth. Of course if that doesn’t convince you then there is also the partnering dance between Coca-Cola and Aurora that somehow didn’t get off the ground. Just how big the market is going to be is still up for grabs.
In a video on TheStreet.com, Canopy Growth CEO Bruce Linton claimed that related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol sleep aids appetite aids sports drinks and medicines and pet care.
If you think the $500 billion figure was a bit too high Constellation Brands COO Bill Newlands predicted that the legal cannabis product market would hit $200 billion plus. “Our View is that in the next ten plus years, this is going to be a $200 billion business worldwide. And some would argue that’s understating the case.”
It’s not difficult to see why the edibles market segment is going to take off.
Smoking is, after all, bad for you. The more difficult question to answer maybe how to profit from what will be a long term market build out and development, one that, ResearchAndMarkets.com has predicted will grow at an astonishing rate of 25.91% CAGR for the years 2018-2022. At the moment almost every major Canadian marijuana company has either a beverage in development or edibles underway in a test kitchen. Edibles and beverages are made from oils and compounds removed from the plants by volatile or non-volatile extraction methods. One way of investing in this developing market lies in investing in those companies that are extracting THC and CBDs from marijuana and then selling it business to business for use in either medical marijuana or as food grade marijuana.
North Bud Farms (CSE: NBUD) is building out its 95 acre site in Low Quebec where it is in within 10 km of a major hydro power plant. Construction is scheduled to be finished Q1 2019 and at the moment is on time and within budget.
The company is also in the process of applying of for a production license under the Access to Cannabis for Medical Purposes Regulation (ACMPR). North Bud has cleverly tagged itself as Marijuana 2.0, in reference to the second wave of legal marijuana slated for October 2019, when the edibles and infused beverage market will be open for business. The company’s strategy is to supply two underserved markets by producing and selling certified pharmaceutical grade cannabis and GMP standard raw cannabis for the food and beverage industry. The company also intends to develop and market new products.
To that end it has recently signed a number of agreements that will help turn its words into action. On September 27, 2018 the company announced that it had signed an agreement with American firm Made By Science to license its cannabinoid infusion technology for food and beverage platform.
On October 17, 2018 North Bud announced that it had created a distribution company, “1017,” so named to commemorate the date of marijuana legalization Canada, and signed a letter of intent to acquire Janey’s, one of the six licensed marijuana accessory distributers in Ontario. Janey’s is also engaged in marijuana product development. North Bud intends to develop multiple products over a variety of product segments under the 1017 brand.
As of November 15, 2018 North Bud Farms, (CSE: NBUD) was trading at $0.25.
Given the predicted explosion in the marijuana consumables and edibles market laying a bet or two on companies in that field makes sense and one such company that bears keeping an eye on is Arev Brands International (CSE: AREV), formally Arev Nutrition Sciences. Arev originally saw life as a developer and marketer of coconut oil based health products. It is focussed on two distinct market sectors, consumer products and manufacturing as an ingredients supplier. Along the way the company also developed a unique extraction technology and this is where they fit into the consumables market segment.
In a press release on Bloomberg the company announced that it had reached a major milestone in extraction development with its partner Alternative Extracts Inc. Using its proprietary extraction system Arev has developed a
system that preserves flavour and aroma and which in the case of beverages may lengthen shelf life. It intends to manufacture finished oil products with proprietary strains bred to specifically address key health issues: anxiety, pain management, central nervous system disorders, insomnia and libido.
Arev also has an exclusive distribution agreement with the award winning full line of BARE Topical products.
In September 2018 the company completed its acquisition of BC Bud Depot. BCBD has one of the world’s largest cannabis seed banks. Over the last 14 years BCBD has won over 40 awards and was the first Canadian company to win an international award with “BC God Bud,” now Canada’s most award winning strain of all time.
On November 15, 2018 AREV was trading at $0.365.
This blog should not be construed as investment advice. Every investor is obligated to perform his or her own due diligence. In the interests of transparency Arev and North Bud Farms are both Momentum Public Relations clients.
- Published in AREV Nutrition Sciences, Blog, Marijuana, Medical Marijuana, NorthBud
Arev Nutrition Sciences Inc. Announces Derek Sider as CFO
Momentum Public Relations
Press Release: February 8 2018
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce Derek Sider has joined the Company as Chief Financial Officer (“CFO”), effective immediately.
Due to the current transaction between the Company and We Grow BC Ltd (“WGBC”), Long Trinh, currently Chief Financial Officer of AREV, has resigned to focus his attention on matters relating to We Grow BC Ltd and closing the transaction with AREV announced on January 17, 2018. The Company is pleased to announce that Derek Sider has been appointed, effective immediately, as Chief Financial Officer (“CFO”).
Derek Sider (Derek) is an experienced financial profession with over 17 years in various international business roles.
Most recently Derek spent 6 years in the mining industry in management roles ranging from M&A to corporate administration and corporate tax. He has participated on a variety of international acquisitions, divestitures, joint ventures and other mining deals with values up to $2 billion. His experience includes corporate finance, corporate tax, securities and corporate law matters, public and private debt, deal negotiation, and corporate structuring.
Prior to that, Derek spent 9 years at PricewaterhouseCoopers, in a number of roles including International Tax in Vancouver and Capital Markets in New York, progressing to the senior manager level.
He has served on a number of non-profits boards, most recently as Treasurer/Finance Committee Chair at the Association of Neighborhood Houses, one of BC’s largest and oldest charities.
Derek is a designated Chartered Professional Accountant (CGA) with a Masters in Science (Tax) with honors and is currently a candidate for a Masters in Business Law (Osgoode Law).
The Company is also pleased to appoint Denby Greenslade as Corporate Secretary of AREV Nutrition Sciences Inc., effective immediately. Ms. Greenslade has over 15 years of corporate secretarial, corporate governance, and securities regulation experience with a focus on the neutraceutical and mining sector in Canada and Mexico. She has served in several senior management and executive roles for companies listed on the Toronto Stock Exchange, TSX Venture Exchange and Canadian Stock Exchange. During her career, she has been involved in numerous transactions and financings, and has led the evaluation, design, implementation and monitoring of governance programs for several junior mining companies.
Further, the Company has hired a consultant with over 12 years of management experience at TELUS to head a number of important Human Resources initiatives. Amongst other things, the consultant will assist with sourcing and place strategic individuals in key roles moving forward.
The Company, effective immediately, has issued 405,000 stock options to Officers and consultants of the Company at a price of $0.56 for a period of 5 years from the issuance date. 25,000 of these options will vest immediately with the remaining 380,000 options on a 2 year vesting schedule: 1/3 immediately, 1/3 at the 1 year mark and the final 1/3 at the end of the second year.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”) produces and delivers functional ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido. .
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2018 TheNewswire – All rights reserved.
- Published in AREV Nutrition Sciences
AREV Nutrition Sciences Inc. Announces a Reverse Takeover Transaction with we Grow BC Ltd.
Momentum Public Relations
Press Release: 2018-01-17
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce a binding agreement (the “Acquisition Agreement”) to acquire 100% of the issued and outstanding shares of We Grow BC Ltd. (“WGBC”).
WGBC is a private company strategically located in Creston British Columbia in the heart of the Kootenay’s, where BC grown marijuana originated, and holds a Cultivation License pursuant to the Access to Cannabis for Medical Purposes Regulations under Health Canada. The Company has scalable production facilities currently consisting of 100 acres of land with 100,000 square feet of indoor space of which 24,000 has been retrofitted for Phase 1 Cultivation.
The Acquisition Agreement provides for each shareholder of WGBC to receive 90,909 shares of AREV in exchange for each share of WGBC based on a $50,000,000 valuation of WGBC. It is anticipated a total of 100,000,000 AREV shares will be issued at a deemed price of $0.50 per AREV Share pursuant to the agreement.
AREV’s intention is to enter into an amalgamation by plan of arrangement where the amalgamation shall take place between a wholly owned subsidiary of AREV and WGBC.
AREV intends to call a Special Annual General meeting in order to approve the transaction and to affix its board of directors to 7 members of which 4 will be designated by WGBC.
The deemed aggregate value of $50,000,000 ($50 million) attributable to such 100,000,000 AREV shares shall be supported by a valuation of WGBC. Also, it is understood that the AREV shares to be issued by AREV to the WGBC Shareholders may be subject to certain resale restrictions including escrow requirements under applicable securities law and policies of the Canadian Securities Exchange (the “CSE”). ;
Both companies will have 5 business days from the date of execution of the Acquisition Agreement to provide the other party complete and commercially reasonable requests for due diligence.
The proposed acquisition of WGBC constitutes a fundamental change under the policies of the “CSE”. and shall be subject to shareholder and CSE approval. Accordingly, trading of AREV shares has been halted pending acceptance of the Acquisition Agreement by the CSE and the acceptance and posting of regulatory filings in connection with the Acquisition Agreement under the Company’s CSE profile.
“We believe this to be the perfect synergy between both companies, with AREV having the extraction technology and finished products and We Grow’s current 24,000 square feet grow facility and up to 100 acre cultivation abilities in the Kootenays,” stated Mike Withrow, AREV Chairman.
Further to the Company’s news release of October 31, 2017, the Company announces that it will not be proceeding with the letter of intent to acquire Verified Plant Genetics and a certain property in Parksville, British Columbia. The Company will revisit this transaction in the future.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Mike Withrow, Chairman.
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”) produces and delivers functional ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
- Published in AREV Nutrition Sciences
AREV Nutrition Sciences Inc. Announces Attendance At Capital Events Bahamas, Conversion Of The Convertible Debenture And Issuance Of Stock Options
Momentum Public Relations
Press Release: January 9, 2018
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CNSX – ARV ), is pleased to announce that that they will be attending the AlphaNorth Capital Conference at the Atlantis Paradise Island Resort in the Bahamas from January 12 – 14, 2018, hosted by Capital Event Conferences. The conference introduces growth-stage companies (Resource, Technology, Biotech, Special Situations) to active top-level capital finance individuals through a day of scheduled one-on-one meetings.
The Company is also pleased to announce that Chiron Capital Inc., a company directly controlled by Mike Withrow, has converted the second of two convertible debentures into units of the Company, each unit consisting of a common share of the Company and a common share warrant of the Company. The total principal amount of the convertible debentures exercised is $300,000. The convertible debentures has been converted into units of the Company at a conversion price of $0.05 per unit with a term ending September 16, 2018.
The conversion of this Convertible Debenture retires long term debt of the C ompany.
After converting the debenture, Chiron Capital Inc., has exercised 2,000,000 warrants at a price of $0.05 per common share for a total cost of $100,000.
If all of Mike Withrow’s convertible securities were converted into common shares of the Company Mike Withrow would control 18,112,000 (42%) of a total of 43,342,800 fully diluted common shares of the Company.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2018 TheNewswire – All rights reserved.
- Published in AREV Nutrition Sciences, Marijuana, Uncategorized
AREV Nutrition Sciences Inc. Announces Shares For Debt
Momentum Public Relations
Press Release: December 14, 2017
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CNSX – ARV ), announces that pursuant to an outstanding debt owed to a previous Director of the Company, it has issued an aggregate of 45,000 common shares at a deemed price of $0.50 share as consideration for the outstanding debt in the Company.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
- Published in AREV Nutrition Sciences
AREV Nutrition Sciences Inc. Orders Second Extraction System for Jamaica
Momentum Public Relations
Press Release: December 13, 2017
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CNSX – AREV ), is pleased to announce that a second extraction system (“extractor”) has been ordered from Alternative Extracts Inc. (AEI) for delivery to Jamaica.
The extractor arrived in Quebec today for modifications that will increase its production capacity from 20 litres to 80 litres. Once the modifications are completed, the extractor will be shipped to a preferred partner in Jamaica that is still to be determined. AREV is in discussions with two potential companies and will select the company that aligns with the company’s vision.
The AEI extractor, removes oils without the use of destructive high-temperature, steam distillation or aggressive solvents and is the only known extractor to combine alcohol and CO 2 supercritical and critical technologies in one efficient process. AREV’s first system from AEI is the only known system to use ethanol, supercritical and subcritical CO2 technologies combined in a single system. It also allows more than one extract to be drawn from a single biomass, and for collection of extract fractions. The second system has been designed specifically to meet the needs of AREV’s partners in Jamaica.
“We are very excited to be ordering our second extractor and look forward to expanding our network with a strategic partner in Jamaica,” says Stephane Maher, CEO of AREV Nutrition Sciences Inc.
More details will be announced as final commitments are made. For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com or www.alternativeextracts.com for information on the company’s extraction systems.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
AREV Nutrition Sciences Inc.
Backgrounder of the AEI IP
FFE enables the extraction of fractions that are mostly lost when using common methods. In addition, yields match or exceed industry standards. The process uses food grade solvents that chill the biomass by adiabatic cooling while extracting at low pressures. The solution is passed into a collection chamber, which is held under vacuum. In this chamber the extraction agent evaporates and is recycled online after filtration and cleaning.
FFE technology is elegant, compact, fully scalable and economical compared to other methods. A fully functional plant with the capacity of processing 1,400 tons/annum of biomass can fit on 150 square metres of total floor space, compared with 1,000 square meters needed for similar capacity solvent or CO 2 plant. These systems are fully scalable and can be expanded to process thousands of acres of hemp, hops or cannabis each harvest.
The key competitive advantages of the FFE process are that it:
- 1. Operates at lower temperatures avoiding the destruction of vital components.
- 2. Produces extract of superior quality and yields to those that are heated or x-rayed or micro waved.
- 3. Uses equipment manufacture and less expensive to operate.
- 4. Significantly speeds up the extraction process.
- 5. Does not generate undesirable effluents.
- 6. Can be used on many different biomass types including Cannabis, industrial hemp and hops and coconut meat.
About AREV
ARE V Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
- Published in AREV Nutrition Sciences, Marijuana